Health and wellness products company USANA Health Sciences (NYSE:USNA) will be announcing earnings results tomorrow afternoon. Here’s what to expect.
USANA beat analysts’ revenue expectations by 2.3% last quarter, reporting revenues of $213.6 million, down 3.4% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ EBITDA estimates and a solid beat of analysts’ EPS estimates.
Is USANA a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting USANA’s revenue to grow 6.7% year on year to $243 million, a reversal from the 8.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.70 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. USANA has missed Wall Street’s revenue estimates three times over the last two years.
Looking at USANA’s peers in the consumer staples segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Lamb Weston delivered year-on-year revenue growth of 4.3%, beating analysts’ expectations by 2.4%, and Simply Good Foods reported revenues up 15.2%, topping estimates by 1.6%. Lamb Weston traded up 9.1% following the results while Simply Good Foods was also up 9.2%.
Read our full analysis of Lamb Weston’s results here and Simply Good Foods’s results here.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. We prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。